Key points are not available for this paper at this time.
Liquid-liquid phase separation (LLPS) has emerged as a fundamental mechanism that orchestrates essential cellular functions. Emerging evidence has established a compelling link between LLPS and core oncogenic processes, including cancer initiation, metastasis, immune evasion, and therapeutic resistance. Among these processes, treatment resistance remains a major barrier to achieving sustained clinical benefit. Aberrant biomolecular condensates formed via LLPS are increasingly recognized as critical mediators of multiple therapy resistance pathways and can be as promising therapeutic targets to overcome treatment failure. In this review, we synthesize emerging insights into how LLPS-derived biomolecular condensates contribute to therapy resistance through diverse mechanisms. We highlight therapeutic strategies aimed at disrupting or exploiting condensate dynamics for reversing cancer therapy resistance. By bridging phase separation biology with resistance mechanisms, this review offers a conceptual framework to assist future research and therapeutic development in oncology.
Hu et al. (2026) studied this question.